TENAPANOR

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C50H66Cl4N8O10S2
Molecular Weight	1145.049
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CN1C[C@@H](C2=CC=CC(=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C3=CC(=CC=C3)[C@@H]4CN(C)CC5=C4C=C(Cl)C=C5Cl)C6=C(C1)C(Cl)=CC(Cl)=C6

InChI

InChIKey=DNHPDWGIXIMXSA-CXNSMIOJSA-N

InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)/t43-,44-/m0/s1

HIDE SMILES / InChI

Description

Tenapanor is an inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3 and reduces sodium absorption in the GI tract, thus increasing intestinal fluid. Ardelyx has completed Phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C) and submitted a new drug application to the U.S. Food and Drug Administration for the treatment of patients with IBS-C. In addition, tenapanor successfully completed phase III clinical trial for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease.

Originator

Approval Year

Doses

Show entries

Dose	Population	Adverse events
50 mg 2 times / day multiple, oral Recommended	unhealthy, adult	Disc. AE: Diarrhea...
90 mg 2 times / day steady, oral Highest studied dose	healthy, mean 29.3 years	Other AEs: Diarrhea, Abdominal pain...
180 mg single, oral Highest studied dose	healthy, mean 37.5 years
60 mg 2 times / day steady, oral Highest studied dose	healthy, mean 37.5 years	Other AEs: Diarrhea...
50 mg 2 times / day multiple, oral Recommended	unhealthy, mean 45 years	Disc. AE: Diarrhea...

Showing 1 to 5 of 5 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Diarrhea	6.5% Disc. AE	50 mg 2 times / day multiple, oral Recommended	unhealthy, adult
Abdominal pain	1 patient	90 mg 2 times / day steady, oral Highest studied dose	healthy, mean 29.3 years
Headache	1 patient	90 mg 2 times / day steady, oral Highest studied dose	healthy, mean 29.3 years
Diarrhea	3 patients	90 mg 2 times / day steady, oral Highest studied dose	healthy, mean 29.3 years
Diarrhea	1 patient	60 mg 2 times / day steady, oral Highest studied dose	healthy, mean 37.5 years

Showing 1 to 5 of 6 entries

Previous1 2Next

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1,737	inhibitor 1,767 substrate 1,037	inhibitor 1,852 substrate 1,217	inhibitor 1,612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1,461 BCRP 699 Cav1.2 45 CYP1A2 1,524 CYP2B6 810 CYP2C8 911 CYP2C19 1,478 OATP1B1 788 OATP1B3 706 OAT1 599 OAT3 642 OCT2 647 MATE1 306 MATE2 263 CYP3A4/5 278	BCRP 561 OATP1B1 406 OATP1B3 350 CYP3A5 395 CYP1A2 1,054 CYP2A6 543 CYP2B6 664 CYP2C8 693 CYP2C19 991 CYP2E1 667	CYP1A2 701 CYP2B6 547 CYP3A4/5 124

Drug as perpetrator

Show entries

Target	Modality	Activity
BCRP 773	inhibitor 3,277	no
CYP1A2 1,692	inducer 1,573	no
CYP1A2 1,692	inhibitor 3,277	no
CYP2B6 1,001	inducer 1,573	no
CYP2B6 1,001	inhibitor 3,277	no

Showing 1 to 5 of 19 entries

Previous1 2 3 4Next

Drug as victim

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1,737	substrate 3,367	minor	M1 13	yes (co-administration study)
BCRP 561	substrate 3,367	no
CYP2E1 667	substrate 3,367	no
OATP1B1 406	substrate 3,367	no
OATP1B3 350	substrate 3,367	no

Showing 1 to 5 of 14 entries

Previous1 2 3Next

Tox targets

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
Cav1.2 49	inhibitor 1,626
hERG 1,647	inhibitor 1,626

Showing 1 to 2 of 2 entries

Previous1Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
AA Blocks	AA00A0DO	https://www.aablocks.com/goods/Goods/detail?id=AA00A0DO
abcr GmbH	AB479209	http://www.abcr.de/shop/en/AB479209
AbMole Bioscience	M7572	http://www.abmole.com/products/tenapanor.html
Adooq BioScience	A14011	https://www.adooq.com/tenapanor.html
Ambeed	A984988	https://www.ambeed.com/products/1234423-95-0.html

Showing 1 to 5 of 20 entries

Previous1 2 3 4Next

PubMed

Title	Date	PubMed
No data available in table

Patents

Sample Use Guides

In Vivo Use Guide

twice-daily oral tenapanor (3, 10, or 30 mg [the latter down-titrated, if needed]) for 8 weeks

Route of Administration: Oral

Show entries

Name

Type

Language

TENAPANOR

Official Name

English

RDX-013 COMPONENT TENAPANOR

Common Name

English

TENAPANOR COMPONENT OF RDX013

Common Name

English

Tenapanor [WHO-DD]

Common Name

English

tenapanor [INN]

Common Name

English

Showing 1 to 5 of 15 entries

Previous1 2 3Next

Show entries

Classification Tree

Code System

Code

Pharmacologic Substance

NCI_THESAURUS

C78276

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Code System

Code

Type

Description

SMS_ID

300000034408

PRIMARY

NCI_THESAURUS

C152555

PRIMARY

DRUG BANK

DB11761

PRIMARY

RXCUI

2199674

PRIMARY

DRUG CENTRAL

5349

PRIMARY

Showing 1 to 5 of 14 entries

Previous1 2 3Next

ACTIVE MOIETY


					WYD79216A6

TENAPANOR

SALT/SOLVATE (PARENT)


					50605O2ZNS

TENAPANOR HYDROCHLORIDE

SMILES

InChI

Originator

Approval Year

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

Drug as perpetrator